The short answer
Yes — Medicare covers Zepbound in 2026, but only one specific version of it: the Zepbound KwikPen. Starting July 1, 2026, the new Medicare GLP-1 Bridge covers the Zepbound KwikPen for weight management at a flat $50 per month for seniors who meet the eligibility rules. The single-dose vials and single-dose pens are not covered.
This is a genuine first. For nearly 20 years, federal law barred Medicare from paying for any drug used purely for weight loss — Zepbound included. The Bridge is the workaround CMS built, and it runs from July 1, 2026 through December 31, 2027.
Not sure whether you qualify? Our 2-minute eligibility quiz walks you through the BMI and health rules.
What is Zepbound?
Zepbound is a brand-name, once-weekly injection from Eli Lilly. Its active ingredient is tirzepatide, which works on two gut hormones (GIP and GLP-1) rather than one — part of why it produces strong results in clinical trials. Zepbound is FDA-approved for chronic weight management, and more recently for moderate-to-severe obstructive sleep apnea in adults with obesity.
That weight-management approval is exactly what unlocks Bridge coverage. Its diabetes-approved sibling, Mounjaro — also tirzepatide — is not part of the Bridge, a distinction we explain below.
The KwikPen detail that trips people up
Here is the part most articles skip, and it matters more than anything else on this page:
The Bridge covers only the Zepbound KwikPen. The single-dose vials and the single-dose pre-filled pens are not covered.
The KwikPen is a multi-dose pen. If your prescription is written for the vials or the single-dose pens, the pharmacy will not apply the $50 Bridge price — and you could be quoted the full cash price by mistake. So when you talk to your prescriber, ask for "Zepbound, the KwikPen" specifically. It is a small wording difference that can be the gap between $50 and $1,000+.
How Medicare covers Zepbound in 2026
You must be enrolled in a Medicare Part D plan — or the drug portion of a Medicare Advantage (MA-PD) plan — to be eligible. But the Bridge operates outside your plan's normal coverage and payment flow: prior authorization and claims are handled through a central CMS processor, not your individual plan. That is why your plan does not need to add Zepbound to its formulary or do anything special for you to qualify.
Under the Bridge, the Zepbound KwikPen costs a flat $50 for a one-month supply — at any dose. Whether you are on the starter dose or the highest maintenance dose, the price is the same.
The Bridge covers three weight-management medications in total: Wegovy (all formulations), the Zepbound KwikPen, and Foundayo. For the full list and the reasoning behind it, see which drugs the $50 Bridge covers.
Who qualifies for Zepbound coverage
To get the Zepbound KwikPen covered under the Bridge, you generally need to:
- Be enrolled in a Medicare Part D or MA-PD plan
- Meet one of three BMI-and-health categories:
- BMI 35 or higher, or
- BMI 30 or higher with a condition such as heart failure, uncontrolled high blood pressure, or chronic kidney disease, or
- BMI 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease
- Have a prescription from a Medicare-accepting provider
- Complete prior authorization, in which your provider attests you are being treated to reduce excess body weight
You do not need a diabetes diagnosis to qualify — the Bridge is built around weight management, not blood sugar. If you need a prescriber, our provider directory lists clinicians who accept Medicare.
What Zepbound costs on Medicare
Under the Bridge, the Zepbound KwikPen costs $50 per month. Without coverage, the cash price runs well over $1,000 a month, so qualifying seniors save on the order of $12,000 a year.
One important catch: that $50 does not count toward your Part D deductible or your annual out-of-pocket maximum ($2,100 in 2026, rising to $2,400 in 2027). The Bridge is a separate track, so the dollars you spend on Zepbound do not help you reach the cap that protects your other Part D drug spending. For how this interacts with the rest of your costs, see how much Wegovy costs on Medicare — the same math applies to Zepbound.
Zepbound vs Mounjaro: why the name matters
This is the most common and most expensive mix-up seniors make.
Zepbound and Mounjaro are the same drug — tirzepatide — but they are approved for different things. Mounjaro is approved for type 2 diabetes and is covered through Medicare's regular Part D rules. Zepbound is approved for weight management and is what the $50 Bridge covers.
If you ask your doctor for "Mounjaro" out of habit, you may end up on the wrong coverage track — or with a denied claim. Ask for Zepbound (the KwikPen) for weight-management coverage. The same trap exists with Ozempic and Wegovy; our Ozempic vs Wegovy vs Zepbound comparison lays out all four side by side.
How to get Zepbound covered — step by step
- Confirm your eligibility. Check your BMI and Part D enrollment with the eligibility quiz.
- Find a Medicare-accepting prescriber. Use the provider directory if you need one.
- Ask for "Zepbound, the KwikPen" — not Mounjaro, and not the vials — for weight management.
- Complete prior authorization. Your provider documents your BMI and qualifying condition. See GLP-1 prior authorization on Medicare for what to expect.
- Fill at your pharmacy and confirm the $50 Bridge price applied before you pay.
What if you don't qualify?
If your BMI or health profile falls outside the Bridge rules, you still have options — including manufacturer savings programs and lower-cost telehealth routes that prescribe tirzepatide for weight loss. We walk through each one in what to do if you don't qualify for the $50 Bridge.
Data note
Data as of June 2026. The Medicare GLP-1 Bridge launches July 1, 2026, and exact rules are set by CMS and your individual plan. Always confirm current coverage with your plan or at Medicare.gov before making decisions, and talk to your doctor about whether Zepbound is right for you.
For the bigger picture, see will Medicare cover weight loss drugs in 2026?